OTIC - OtonomyAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $4.93 | Open | |
| Volume | Market Cap | 77.33M | |
| Yield | Last Dividend |
| Otitis Drug Market Analysis by Sanofi, B... | 11/11/20 |
| Otitis Drug Market By Type (Acute Otitis Media, Otitis Media with Effusion and Chronic Otitis Media with Effusion), Treatment Type (Medication and Sur... | |
| Global Meniere's Disease Drug Market to ... | 11/06/20 |
| Global Meniere's Disease Drug Market research report has been produced with the systematic gathering of market information for industry. All this info... | |
| Otonomy, Inc. (NASDAQ:OTIC) Given Consen... | 10/24/20 |
| Otonomy, Inc. (NASDAQ:OTIC) has earned a consensus rating of ???Buy??? from the six brokerages that are currently covering the stock, MarketBeat.com r... | |
| Booming Growth of Vertigo Drugs Market t... | 10/15/20 |
| The global analysis of Vertigo Drugs Market and its upcoming prospects have recently added by HealthCare Intelligence Markets to its extensive reposit... | |
| Global Meniere???s disease drug Market 2... | 09/28/20 |
| This Global Meniere???s disease drug Market research report is a sure solution to get market insights with which you can visualize market place clearl... | |
| The Daily Biotech Pulse: Gilead's Filgot... | 08/19/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) Avenue Therapeutics Inc (NASDAQ: ATXI ) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI )... | |
| Otonomy to Report Second Quarter 2020 Fi... | 07/28/20 |
| Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020 | |
| The Daily Biotech Pulse: Midatech Shelve... | 07/23/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: ... | |
| The Daily Biotech Pulse: 2 IPOs, Nabriva... | 07/17/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 16) AC ... | |
| ALK Enters into Co-Promotion Agreement w... | 06/17/20 |
| ROUND ROCK, Texas, June 17, 2020 /PRNewswire/ -- ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF) a global, research-driven pharmaceutical company that focus... | |
| Otonomy to Host Pipeline Program Update ... | 06/08/20 |
| SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative??? | |
| Otonomy Reports First Quarter 2020 Finan... | 05/07/20 |
| Conference call to review status of clinical trials and timing to results to be held in June | |
| Tunisia-coronavirus: speculators lining ... | 04/03/20 |
| The fight against the spread of the coronavirus in Tunisia has brought with it the fight against one of the most deeply rooted phenomena, and which po... | |
| Reduction in fuel subsidy behind increas... | 01/12/20 |
| Tunisians and civil society activists have reiterated, in recent days, their discontent after a 30% increase were recorded in some food prices such as... | |
| The Daily Biotech Pulse: Acorda Surges A... | 01/03/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) A... | |
| Otonomy Inc (OTIC): Are Hedge Funds Righ... | 12/16/19 |
| Is Otonomy Inc (NASDAQ:OTIC) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so becau... | |
| Otonomy (OTIC) Reports Q3 Loss, Lags Rev... | 11/05/19 |
| Otonomy (OTIC) delivered earnings and revenue surprises of 26.67% and -59.68%, respectively, for the quarter ended September 2019. Do the numbers hold... | |
| Analysts Estimate Otonomy (OTIC) to Repo... | 10/28/19 |
| Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with t... | |
| Otonomy, Inc. (OTIC) CEO David Weber on ... | 05/06/19 |
| Otonomy, Inc. (NASDAQ:OTIC) Q1 2019 Results Earnings Conference Call May 06, 2019, 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Da... | |
| Otonomy (OTIC) Reports Q1 Loss, Misses R... | 05/06/19 |
| Otonomy (OTIC) delivered earnings and revenue surprises of 15.22% and -40.92%, respectively, for the quarter ended March 2019. Do the numbers hold clu... | |
| Otonomy beats by $0.06, misses on revenu... | 05/06/19 |
| No summary available. | |
| Otonomy begins mid-stage trial of OTO-31... | 04/11/19 |
| No summary available. | |
| Otonomy (OTIC) Presents At Cowen And Com... | 03/12/19 |
| No summary available. | |
| GME, NVTA, PS and SOI among after hours ... | 03/04/19 |
| No summary available. | |
| Here Is Otonomy | 01/22/19 |
| No summary available. | |
| Here Is Otonomy | 01/22/19 |
| No summary available. | |
| Otonomy (OTIC) Presents At 37th Annual J... | 01/11/19 |
| No summary available. | |
| Otonomy (OTIC) Presents At 37th Annual J... | 01/11/19 |
| No summary available. | |
| Date | 2020-11-04 (AMC) | Est. (EPS/Rev.) | ($0.24)/ 50K |
| Actual (EPS/Rev.) | $-0.22/ $50.00 K | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Mojo Day Trading | ProTrader Mike | 46.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
